Copyright
©The Author(s) 2018.
World J Gastrointest Oncol. Oct 15, 2018; 10(10): 336-343
Published online Oct 15, 2018. doi: 10.4251/wjgo.v10.i10.336
Published online Oct 15, 2018. doi: 10.4251/wjgo.v10.i10.336
Table 4 The standardized uptake values used to define clinically significant 18F-fluorodeoxyglucose positron emission tomography/computed tomography positivity for hepatocellular carcinoma
Ref. | Year | No. of patients | Study model | SUV values | ||
SUVmax | TSUVmax-to-LSUVmax | TSUVmax-to-LSUVmean | ||||
Lee et al[34] | 2009 | 59 | LT | 3 | 1.15 | 1.35 |
Song et al[35] | 2012 | 83 | LRT | 4 | 1.45 | 1.9 |
Lee et al[36] | 2015 | 280 | LDLT | 4.4 | ||
Hsu et al[37] | 2016 | 147 | LDLT | 4.8 | 2 | |
Hong et al[38] | 2016 | 123 | LDLT | 1.1 | ||
Boussouar et al[39] | 2016 | 28 | LT | 1.15 | ||
Bailly et al[40] | 2016 | 34 | LT | 1.15 | ||
Lin et al[41] | 2017 | 65 | LT | 3.8 | 1.49 | 1.69 |
- Citation: Yaprak O, Acar S, Ertugrul G, Dayangac M. Role of pre-transplant 18F-FDG PET/CT in predicting hepatocellular carcinoma recurrence after liver transplantation. World J Gastrointest Oncol 2018; 10(10): 336-343
- URL: https://www.wjgnet.com/1948-5204/full/v10/i10/336.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v10.i10.336